Medigold Health CEO, Alex Goldsmith, named as one of the UK’s most ambitious business leaders

Supported by The Telegraph, LDCs ‘Top 50 Most Ambitious Business Leaders’, shines a light on the inspiring leaders running the UK’s most successful medium sized businesses.

Recognised as the ‘unsung heroes of the British economy,’ the individuals featured in the list demonstrate ambition, diversity and dynamism, and we are delighted to announce that our very own CEO Alex Goldsmith, has been named as one of the Top 50.

Applauded for his track record of delivering exceptional business results and sound investment decisions, Alex consistently demonstrates the drive and determination to succeed whilst building a business where his people feel truly valued.

Alex said of his achievement; 

“I am proud to be named in LDC’s Top 50 Most Ambitious Business Leaders. It must be said however that this accolade is as much a reflection of the team and people behind me as it is a personal achievement. I believe this represents recognition of the hard work and dedication shown by all within Medigold Health and shows how our people have followed the vision I have outlined for the growth of our business.”

Craig Hinde of LDC also commented on Alex’s inspiring journey;

“Alex was suddenly parachuted into the family business from an entirely different career, learning fast to help his father during a difficult time. He rose to the challenge, and found he had a natural flair for entrepreneurship, taking calculated risks that have helped Medigold Health build an unrivalled reputation in employee wellness. Revenues have grown under his leadership, yet he never rests on his laurels, investing consistently in R&D. A true leader and innovator, Medigold Health will surely stay ahead of the pack over the coming years.”

Alex’s story features in the first instalment of the Top 50 series, entitled ‘Thinking Big’, read the full story here:

Established in 1981 LDC is a leading player in the private equity mid-market and is able to provide up to £100m of funds for buyouts and development capital transactions in UK unquoted companies.